ACHV: Looking Ahead to Resubmission
By John Vandermosten, CFANASDAQ: ACHVREAD THE FULL ACHV RESEARCH REPORTAchieve Life Sciences, Inc. (NASDAQ: ACHV) reported second quarter results, introducing…
4,776€
-8,42%
Echtzeit-Aktienkurs Aclaris Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Aclaris Therapeutics Inc. Aktie
Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
…
Stifel raises Aclaris Therapeutics price target to $4 on pipeline
Stifel raises Aclaris Therapeutics price target to $4 on pipeline…
Aclaris Therapeutics: Zukunftsperspektiven im Bereich der Immunentzündungskrankheiten - Guggenheim empfiehlt den Kauf und sieht ein Potenzial von 159 %!
Strategische Ausrichtung und Kernkompetenzen Aclaris Therapeutics (ACRS) ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich auf die Entwicklung neuartiger…
Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates Transcript
…
MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates
MARKER THERAPEUTICS (MRKR) delivered earnings and revenue surprises of +80.49% and +83.83%, respectively, for the quarter ended December 2025. Do…
Aclaris Therapeutics, Inc. (ACRS) Discusses Positive Interim Results From ATI-052 Phase 1a Trial and Potential Therapeutic Advantages Transcript
…
What Makes Aclaris Therapeutics (ACRS) a Strong Momentum Stock: Buy Now?
Does Aclaris Therapeutics (ACRS) have what it takes to be a top stock pick for momentum investors? Lets find out.…
Aclaris Therapeutics, Inc. (ACRS) Discusses At 2025 R&D Day (Transcript)
…
Aclaris Therapeutics stock soars after positive Phase 2a trial results By Investing.com
Aclaris Therapeutics stock soars after positive Phase 2a trial results…
Areteia Therapeutics gibt die Ernennung von Donald J. Hayden, Jr. und Ian F. Smith in den Vorstand bekannt
CHAPEL HILL, North Carolina--(BUSINESS WIRE)--Areteia Therapeutics, Inc. („Areteia“) gab heute bekannt, dass der Vorstand mit sofortiger Wirkung Donald J. Hayden,…
Aclaris Therapeutics Aktie: Frische Impulse sorgen für Bewegung!
Die Aclaris Therapeutics Aktie verzeichnet derzeit eine bemerkenswerte Entwicklung am Markt. Nach einem monatlichen Rückgang von 11,98% hat sich der…
Aclaris Therapeutics: History Of Failures, And Recent Acquisition Of A Blockbuster Potential Molecule
…
Areteia Therapeutics präsentiert auf der 43. jährlichen J.P. Morgan Healthcare Conference am Dienstag, den 14. Januar 2025
CHAPEL HILL, North Carolina--(BUSINESS WIRE)--Areteia Therapeutics, Inc. („Areteia“), ein Biotechnologieunternehmen im klinischen Stadium, das neuartige Entzündungs- und Immuntherapien entwickelt, mit…
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium
SEATTLE, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical…
Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
Aclaris Therapeutics to Participate in the Piper Sandler
36th Annual Healthcare Conference…
Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit
SEATTLE, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced…
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline…
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference…
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) INVESTOR ALERT: Investors With Large Losses in Verve Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) INVESTOR ALERT: Investors With Large Losses in Verve Therapeutics, Inc. Should Contact Bernstein Liebhard LLP…
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline…
Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
ATLANTA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company…
Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript
…
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company…
Cryopyrin-Associated Periodic Syndrome Drug Pipeline Report 2024: Therapeutic Developments for Zydus Cadila, Novartis, Inflazome, Roche, Aclaris Therapeutics, and Mabpharm
Dublin, April 25, 2024 (GLOBE NEWSWIRE) -- The "Cryopyrin-Associated Periodic Syndrome - Pipeline Insight, 2024" report has been…
Anthos Therapeutics Announces Appointment of Bill Meury as CEO
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (Anthos), is a clinical-stage company developing innovative…
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
PURCHASE, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a…
NeuBase Therapeutics Announces Receipt of Notice from Nasdaq
PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today reported…
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company…
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused…